http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 08:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html <p>SHANGHAI, Aug 20, 2026 - (JCN Newswire) - - - Sales of HuaTangNing reached 3.055 million packs in the first half of 2026, representing a 73% year-on-year increase; revenue hit RMB378.9 million, up 74% year-on-year. The in-house commercialization drive maintained robust growth with continuously improved operational efficiency.</p><p>- Expanded manufacturing scale lifted gross profit margin substantially to 61.8%, a year-on-year rise of 7.6 percentage points.</p><p>- Profit generated from commercial operations doubled year-on-year, and loss narrowed markedly to RMB30.2 million after excluding one-off income, demonstrating a clear path to fullscale profitability.</p><p>- Selling expense-to-revenue ratio stabilized at 33.5%, http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+2026+Interim+Results/26963003.html Thu, 20 Aug 2026 08:02:00 -0400 02552 2552 A.23093189 A.50207248 HUMDF O.00386324 O.13316223 O.38747766 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html <div class="xn-content"> <ul type="disc"><li><i>First </i><i>glucokinase-activator (GKA)</i><i> approval outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location> </i></li><li><i>Approval supports a differentiated approach to </i><i>T</i><i>ype 2 diabetes (T2D) management</i></li><li><i>Hong Kong </i><i>will serve as H</i><i>ua Medicine's</i><i> launchpad for </i><i>international market</i><i> expansion</i></li></ul><p><span class="legendSpanClass"><location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location> and <location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="HongKong:2552" idsrc="xmltag.org" >Hua Medicine</span> ("the Company", Hong Kong Stock Exchange Stock Code: <span id="spanHghlt6d35">2552.HK</span>) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the <span>Department of Health of the Hong Kong Special Administrative Region</span> of <location value="LC/cn" http://www.streetinsider.com/PRNewswire/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26095028.html Tue, 03 Mar 2026 00:48:00 -0400 2552 A.20822773 A.23093189 A.60012007 O.13316223 O.20370956 O.38747766 O.48414375 http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26105745.html <p>Shanghai, Hong Kong, Mar 3, 2026 - (JCN Newswire) - - - First glucokinase-activator (GKA) approval outside mainland China</p><p>- Approval supports a differentiated approach to Type 2 diabetes (T2D) management</p><p>- Hong Kong will serve as Hua Medicine&apos;s launchpad for international market expansion</p><p>Hua Medicine (&quot;the Company&quot;, Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.</p><p>Under Hong Kong&apos;s http://www.streetinsider.com/Press+Releases/Hua+Medicine+Announces+the+Approval+of+Dorzagliatin+for+Marketing+in+Hong+Kong+SAR%2C+China/26105745.html Mon, 02 Mar 2026 22:14:00 -0400 02552 2552 A.20822773 A.23093189 A.60012007 HUMDF O.13316223 O.20370956 O.38747766 O.48414375